Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.21% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-11
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.21%, a 3.95% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.91%, a 11.54% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 3.99%, a 9.32% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.05%, a 11.96% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month |
|---|---|---|---|
| 2026-06-30 | 4.21% 10-Q · filed 2026-08-11 | 4.21% 10-Q · filed 2026-08-11 | |
| 2026-03-31 | 3.91% 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | 3.99% 10-Q · filed 2025-11-13 | 4.42% 10-Q · filed 2025-11-13 | |
| 2025-06-30 | 4.05% 10-Q · filed 2026-08-11 | 4.42% 10-Q · filed 2026-08-11 | |
| 2025-03-31 | 4.42% 10-Q · filed 2026-05-12 | ||
| 2024-09-30 | 4.40% 10-Q · filed 2025-11-13 | 4.60% 10-Q · filed 2025-11-13 | |
| 2024-06-30 | 4.60% 10-Q · filed 2025-08-11 | 4.60% 10-Q · filed 2025-08-11 | |
| 2024-03-31 | 4.32% 10-Q · filed 2025-05-09 | ||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-18 | 4.46% 10-Q · filed 2024-11-18 | |
| 2023-06-30 | 3.68% 10-Q · filed 2024-08-09 | 4.46% 10-Q · filed 2024-08-09 | |
| 2023-03-31 | 4.46% 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |